By Fineline Cube 
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has completed a private placement, raising RMB 1.796 billion (USD 246 million). The funds will be allocated to the research and development (R&D) of core products and the construction of in-house R&D facilities. Notable investors included Taikang Asset Management, Ping An Fund, and the state-backed Wuxi Zhanxin Private Equity Fund.
Pipeline Highlights
Dizal Pharma’s pipeline includes seven globally competitive assets. Sunvozertinib, an EGFR inhibitor, received marketing approval in China in August 2023, while Gaoruizhe (golidocitinib), a JAK1 inhibitor, was approved in June 2024. Both drugs were included in China’s 2024 National Reimbursement Drug List (NRDL). The company is also advancing programs such as the non-covalent LYN/BTK inhibitor DZD8586 and the highly selective EGFR tyrosine kinase inhibitor (TKI) DZD8586.-Fineline Info & Tech